Individuals with chronic obstructive pulmonary disease (COPD) who continue to experience symptoms or flare-ups despite treatment may qualify for a research study evaluating an investigational medication.
COPD
Age Range:
40 to 80
Gender:
Male and Female
Location:
West Chester, Pennsylvania
About the Study
This research study is evaluating lunsekimig, an investigational medication administered by subcutaneous injection, designed to target inflammatory pathways involved in COPD exacerbations and airway inflammation.
Qualifications
You May Be Eligible If:
-Are 40 to 80 years of age
-Have been diagnosed with COPD
-Continue to experience symptoms or COPD flare-ups despite treatment
-Have a history of moderate or severe COPD exacerbations within the past year
-Are currently using COPD controller medications as prescribed
-May have elevated eosinophil levels (blood testing required)
-Are willing and able to attend study visits and follow study procedures
FEATURED STUDIES
General Anxiety Disorder
Individuals with generalized anxiety disorder (GAD) who experience ongoing worry, stress, or difficulty managing anxiety symptoms may qualify for a
COPD
Individuals with chronic obstructive pulmonary disease (COPD) who continue to experience symptoms or flare-ups despite treatment may qualify for a
MDD Study
Adults 18 to 65 years of age with Major Depressive Disorder (MDD) may qualify for a clinical research study evaluating
Chronic Obstructive Pulmonary Disease (COPD)
Adults 40–75 who have COPD and experienced a flare-up in the past year may qualify for a study evaluating an
Post-Traumatic Stress Disorder (PTSD)
Adults 18 and older living with post-traumatic stress disorder (PTSD) may qualify for a clinical research study evaluating an investigational
Bronchiectasis
Individuals with bronchiectasis who experience frequent flare-ups or ongoing respiratory symptoms may qualify for a research study evaluating a home